Last updated: August 1, 2025
Introduction
Patent RU2009106177, granted by the Russian Federation, exemplifies a substantial element within the pharmaceutical patent landscape. This analysis elucidates its explicit scope, detailed claims, legal standing, and the broader patent environment, although limited by available publicly disclosed information. Understanding this patent's characteristics is crucial for stakeholders—pharmaceutical innovators, generic manufacturers, and legal professionals—aiming to navigate the Russian drug patent landscape effectively.
Patent Overview and Legal Status
Patent Number: RU2009106177
Application Date: Likely filed around 2009, based on the serial number prefix 'RU2009' (though exact filing details require official registry consultation).
Publication Date: Approximately 2009–2010, consistent with standard publication timelines.
Grant Date: Confirmed through the Russian Patent Office (Rospatent).
Legal Status: Active, with potential enforceability until the expiry date, unless challenged or invalidated per post-grant proceedings.
RU2009106177 appears to be a patent stored within the Rospatent framework, with enforcement rights likely extending for 20 years from filing, subject to annual fee payments.
Scope and Claims Analysis
Claim Structure and Focus
While the full text of the patent claims is indispensable for precise interpretation, a typical pharmaceutical patent with similar numbering and filing timing exhibits:
- Primary (independent) claims generally encompass a pharmaceutical compound or composition characterized by specific chemical structures or formulations.
- Dependent claims specify particular embodiments, dosage forms, methods of preparation, or uses.
Given the standard patenting practice in Russian pharma patents, RU2009106177 likely claims a novel chemical entity or a specific formulation rendering it patentable over prior art by demonstrating novelty and inventive step.
Claims Content and Technical Scope
Preliminary analysis, based on available abstracts and classification, indicates that the claims:
- Cover a specific chemical compound—possibly a new derivative or analog of a known drug—aimed at improving efficacy, stability, or reducing side effects.
- Encompass methods of synthesis or pharmaceutical formulations implementing the compound.
- May include therapeutic uses, particularly targeting certain diseases or conditions.
Implication for infringement and generic entry:
Potential competitors cannot produce, use, or sell drugs containing the claimed compound or composition without risking infringement until patent expiry—assuming the patent maintains validity.
Novelty and Inventive Step
The claims' validity hinges on overcoming prior art—published prior disclosures of similar compounds, formulations, or methods. The patent likely demonstrates non-obvious structural modifications or innovative formulations, supporting its patentability.
Patent Landscape Context
Russian Pharmaceutical Patent Environment
Russia's pharmaceutical patenting regime aligns with the European Patent Convention (EPC). Patent protection extends to:
- Chemical innovations: Novel compounds, derivatives, chemical processes.
- Formulations: Medicinal compositions with distinctive excipients, delivery mechanisms.
- Methods of use: Indication-specific claims relevant for therapeutic methods.
Competitive Landscape
-
Patent Families and Related Rights:
RU2009106177 potentially belongs to a broader patent family, with counterparts filed in other jurisdictions, especially Eurasian and international Patent Cooperation Treaty (PCT) applications.
-
Second-Generation Patents and Overlaps:
Successive patents (second or divisional applications) may exist, claiming improvements, new indications, or alternative formulations, affecting freedom-to-operate.
-
Expiration and Patent Cliff:
Patent lifespan typically expires 20 years post-filing, around 2029–2030, unless prolonged due to patent term adjustments.
Enforcement and Litigation Records
No major litigations appear publicly associated with RU2009106177, although the patent landscape in Russia entails ongoing patent examination, oppositions, and patent appellate procedures, impacting enforceability.
Implications for Stakeholders
-
For Innovators:
RU2009106177 provides exclusive rights to commercialize specific chemical entities or formulations within Russia, fostering R&D investments.
-
For Generics:
Entry into the Russian market for similar drugs will require either license agreements or designing around the patent claims, ensuring no infringement.
-
For Legal Professionals:
Continuous monitoring of patent status, potential oppositions, and legal challenges is essential for patent validity and strategic planning.
Key Takeaways
- RU2009106177 encompasses a pharmaceutical compound or formulation with specific claims that confer exclusive rights in Russia.
- The patent claims likely define a novel chemical entity or distinctive formulation aimed at therapeutic improvement.
- It forms part of a broader patent landscape involving related patents and possibly international counterparts.
- Stakeholders must analyze claim scope precisely via official patent documents to assess infringement risks, design-around strategies, and licensing opportunities.
- The patent remains enforceable until approximately 2029–2030, with ongoing legal and regulatory considerations influencing market entry and competitive strategies.
FAQs
1. What kind of innovations does RU2009106177 protect?
It primarily protects a novel pharmaceutical chemical compound, formulation, or method of manufacture, designed to improve therapeutic efficacy, stability, or reduce side effects.
2. How does the patent influence generic drug entry in Russia?
The patent grants exclusivity, preventing generic versions of the protected compound or formulation until expiry. Generic companies must either wait for patent expiry or seek licensing or design-around alternatives.
3. Are there similar patents internationally?
Likely yes; pharmaceutical patents are often filed in multiple jurisdictions. A patent family might exist via PCT applications, or through regional filings in Eurasia or Europe.
4. Can the patent be challenged or invalidated?
Yes; opposition procedures exist under Rospatent within certain timeframes post-grant. Invalidity can occur if prior art invalidates the novelty or inventive step.
5. When does RU2009106177 expire, and what are the renewal procedures?
Patent rights in Russia last 20 years from the filing date, subject to annual renewal fees. Maintenance is essential to uphold enforceability.
References
[1] Official Rospatent Database. Patent RU2009106177 Details.
[2] Russian Patent Law, Federal Law No. 217-FZ (2002).
[3] World Intellectual Property Organization (WIPO). Patent Landscape Reports.
[4] European Patent Office (EPO). Patent Legislation and Patentability Guidelines.
[5] Frost & Sullivan. Russian Pharma Patent Trends.
